Navigation Links
CooperVision Launches Science and Technology (S&T) Awards Program
Date:5/7/2013

PLEASANTON, Calif., May 7, 2013 /PRNewswire/ -- CooperVision is pleased to announce a Science and Technology (S&T) Awards Program. The goal of this awards program is to bring recipients and CooperVision scientists together to explore new areas of technology advancement. The awards program will address ocular surface health and anterior segment symptomology through advancement of technologies including, but not limited to materials, devices and compounds.

"Our goal is to support science and encourage a focus on unmet needs that can be translated back to our community. I am pleased that the CooperVision Science and Technology Awards will provide scientists in academia and research institutes a substantive opportunity to pursue emerging ideas and concepts in a meaningful and focused way," said Arthur Back , Chief Technology Officer for CooperVision.

The CooperVision S&T Awards Program comprises of two awards: The CooperVision Seedling Award and the CooperVision Translational Research Award.

The CooperVision Seedling Award is intended to incentivize collaborations with CooperVision in a new research area for a one year period. This award enables investigators to generate preliminary data that could be used toward a future CooperVision Translational Research Award. Early-career and established faculty in areas other than contact lens research are strongly encouraged to apply. A CooperVision Seedling Award provides funding for one year and is awarded on a one-time basis only. The maximum total cash amount for a CooperVision seedling is $100,000, including indirect costs. 

The CooperVision Translational Research Award is a multi-year award for a substantive translational research project. Early-career and established faculty in areas other than contact lens and research are strongly encouraged to apply. Collaboration between basic scientists, engineers and clinicians are strongly encouraged in order to achieve high-quality, innovative translational research. A CooperVision Translational Research Award provides funding for up to two years, totaling up to $400,000, including indirect costs.  A maximum of $250,000 can be requested for any one year. A CooperVision Translational Research Award may be considered for renewal.

For information of the application process and materials, please visit us at http://coopervision.com/our-company/science-and-technology-awards.

About CooperVision

CooperVision, a unit of The Cooper Companies, Inc. (NYSE: COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges; such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, thereby creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO).  Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value.  Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women.  Headquartered in Pleasanton, CA, Cooper has approximately 7,800 employees with products sold in over 100 countries.  For more information, please visit www.coopercos.com.


'/>"/>
SOURCE CooperVision
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CooperVision Renews Its Support of U.S. Military Personnel
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
4. Mylan Launches Generic Version of Zyprexa® Tablets
5. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
6. American Academy of Family Physicians Foundation Launches Cities for Life
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
9. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
10. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
11. Practice Fusion Launches API to Democratize Lab Integrations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2015 through 2022. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2017)... , Feb. 23, 2017  This report analyzes ... by the following Products: Intermediates, Analytical, ... the report include Pharmaceuticals, and Agrochemicals. The report provides ... , Europe , and Rest ... the period 2015 through 2022. Also, a six-year historic ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
(Date:2/24/2017)... ... , ... An in-depth computational analysis of genetic variants implicated in both schizophrenia ... that may explain why susceptibility to one of the disorders could place individuals at ... in the journal npj Schizophrenia. , “There is a wealth of genomic data ...
(Date:2/24/2017)... NY (PRWEB) , ... February 24, 2017 , ... In ... needs to be a top priority because it’s not if you will be attacked, ... safety, especially when it comes to digital health care. , Improvements in auditing and ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
Breaking Medicine News(10 mins):